-
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
As a community, we are crushed to hear the news from Pfizer that their Phase […]
-
Consensus Statement Featuring Expert Insights from PPMD’s Certified Duchenne Care Centers on Access to Novel Therapies for Duchenne Published
PPMD is excited to share that a consensus statement providing insights from clinicians who care […]
-
Roche Announces Phase II Open-Label SHIELD DMD Study to Assess Effect of Satralizumab on Bone Health in Duchenne
Today Roche announced plans for the SHIELD DMD study, a phase II open-label study to […]
-
During a busy season, we must take things one day at a time
I feel relaxed — refreshed, even. We’ve had almost two weeks at home without any […]
-
Summer Fun: Accessible Activities for All Ages and Interests
As the school year wraps up, we are all looking forward to a fun-filled […]
-
Advisory board named to shepherd Duchenne MD candidate
Satellos Bioscience has established a clinical advisory board, with experts in drug development and genetic […]
-
Three years of CAP-1002 still stabilizing arm, heart function
After three years of treatment with Capricor Therapeutics’ experimental cell therapy CAP-1002, people with Duchenne […]
-
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002
Capricor Therapeutics has announced positive 3-year results from the ongoing HOPE-2 open-label extension (OLE) study […]
-
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Read the full news release HERE Capricor Therapeutics, which received early funding from CureDuchenne, has […]
